FDG-PET and hepatocellular carcinoma

Journal of Gastroenterology

Volumn 39, Issue 10, 2004, Pages 1017-1018

  Kashiwagi, Toru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEXOKINASE;

ANGIOGRAPHY; BONE METASTASIS; BONE SCINTISCANNING; CANCER CELL; CANCER LOCALIZATION; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL PRACTICE; DIAGNOSTIC VALUE; DRUG METABOLISM; DRUG TRANSPORT; ECHOGRAPHY; EDITORIAL; ENZYME ACTIVITY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LUNG METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX RADIOGRAPHY;

CARCINOMA, HEPATOCELLULAR; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 8544265330     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1458-y     Document Type: Editorial

References (13)

1. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological application of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23: 1641-74.
2. Giannopoulou C. The role of SPET and PET in monitoring tumor response to therapy. Eur J Nucl Med Mol Imaging 2003;30:1173-200.
3. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: Characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-9.
4. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Pinson W. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-6.
5. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94:3314-9.
6. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatology 2000; 32:792-7.
7. 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepato-Gastroenterology 2003;50:2154-6.
8. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36: 1811-7.
9. 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver. Liver 2000;20:487-90.
10. Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965-9.
11. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192-7.
12. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961-8.
13. Schoder H, Erdi YE, Larson SM, Yeung HWD. PET/CT: A new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 2003;30:1419-37.